Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.

ABSTRACT:

Background

Extensive prostate specific antigen screening for prostate cancer generates a high number of unnecessary biopsies and over-treatment due to insufficient differentiation between indolent and aggressive tumours. We hypothesized that seminal plasma is a robust source of novel prostate cancer (PCa) biomarkers with the potential to improve primary diagnosis of and to distinguish advanced from indolent disease.

Methodology/principal findings

In an open-label case/control study 125 patients (70 PCa, 21 benign prostate hyperplasia, 25 chronic prostatitis, 9 healthy controls) were enrolled in 3 centres. Biomarker panels a) for PCa diagnosis (comparison of PCa patients versus benign controls) and b) for advanced disease (comparison of patients with post surgery Gleason scor

SUBMITTER: Neuhaus J 

PROVIDER: S-EPMC3691205 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature